Elevance Health, Inc. (ELV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 20B 40B 60B Q3 '16: 21.4B Q4 '16: 21.7B Q1 '17: 22.5B Q2 '17: 22.4B Q3 '17: 22.4B Q4 '17: 22.7B Q1 '18: 22.5B Q2 '18: 22.9B Q3 '18: 23.3B Q4 '18: 23.4B Q1 '19: 24.7B Q2 '19: 25.5B Q3 '19: 26.7B Q4 '19: 27.4B Q1 '20: 29.6B Q2 '20: 29.3B Q3 '20: 31.2B Q4 '20: 31.8B Q1 '21: 32.4B Q2 '21: 33.9B Q3 '21: 35.8B Q4 '21: 36.6B Q1 '22: 38.1B Q2 '22: 38.6B Q3 '22: 39.9B Q4 '22: 39.9B Q1 '23: 42.2B Q2 '23: 43.7B Q3 '23: 42.8B Q4 '23: 42.6B Q1 '24: 42.6B Q2 '24: 43.9B Q3 '24: 45.1B Q4 '24: 45.4B Q1 '25: 48.9B Q2 '25: 49.8B Q3 '25: 50.7B Q4 '25: 49.7B Q1 '26: 50.2B Q2 '26: 50.5B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

0 1.5B 3B 4.5B Q3 '16: 1.1B Q4 '16: 652.3M Q1 '17: 1.6B Q2 '17: 1.2B Q3 '17: 982M Q4 '17: 381M Q1 '18: 1.9B Q2 '18: 1.6B Q3 '18: 1.2B Q4 '18: 750M Q1 '19: 1.9B Q2 '19: 1.4B Q3 '19: 1.5B Q4 '19: 1.1B Q1 '20: 2.2B Q2 '20: 3.4B Q3 '20: 201M Q4 '20: 605M Q1 '21: 2.2B Q2 '21: 2.1B Q3 '21: 2.1B Q4 '21: 1.3B Q1 '22: 2.4B Q2 '22: 2.3B Q3 '22: 2.3B Q4 '22: 1.3B Q1 '23: 2.8B Q2 '23: 2.6B Q3 '23: 1.8B Q4 '23: 1.3B Q1 '24: 3B Q2 '24: 2.8B Q3 '24: 1.4B Q4 '24: 673M Q1 '25: 3.2B Q2 '25: 2.4B Q3 '25: 1.3B Q4 '25: 309M Q1 '26: 2.1B Q2 '26: 1.8B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

0 800M 1.6B 2.4B Q3 '16: 617.8M Q4 '16: 368.4M Q1 '17: 1B Q2 '17: 855.3M Q3 '17: 747M Q4 '17: 1.2B Q1 '18: 1.3B Q2 '18: 1.1B Q3 '18: 960M Q4 '18: 424M Q1 '19: 1.6B Q2 '19: 1.1B Q3 '19: 1.2B Q4 '19: 934M Q1 '20: 1.5B Q2 '20: 2.3B Q3 '20: 222M Q4 '20: 551M Q1 '21: 1.7B Q2 '21: 1.8B Q3 '21: 1.5B Q4 '21: 1.2B Q1 '22: 1.8B Q2 '22: 1.6B Q3 '22: 1.6B Q4 '22: 865M Q1 '23: 2B Q2 '23: 1.9B Q3 '23: 1.3B Q4 '23: 856M Q1 '24: 2.2B Q2 '24: 2.3B Q3 '24: 1B Q4 '24: 418M Q1 '25: 2.2B Q2 '25: 1.7B Q3 '25: 1.2B Q4 '25: 547M Q1 '26: 1.8B Q2 '26: 1.5B Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 2.5B 5B 7.5B Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 98M Q3 '19: 745M Q4 '19: 1.1B Q1 '20: 2B Q2 '20: 2.2B Q3 '20: 2.2B Q4 '20: 2.5B Q1 '21: 2.3B Q2 '21: 2.6B Q3 '21: 2.9B Q4 '21: 3.1B Q1 '22: 2.9B Q2 '22: 3.1B Q3 '22: 3.4B Q4 '22: 3.6B Q1 '23: 3.5B Q2 '23: 4.3B Q3 '23: 4.6B Q4 '23: 4.8B Q1 '24: 3.8B Q2 '24: 4.8B Q3 '24: 5.1B Q4 '24: 6B Q1 '25: 5B Q2 '25: 5.3B Q3 '25: 5.4B Q4 '25: 5.5B Q1 '26: 5.5B Q2 '26: 5.5B Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-2.5B 0 2.5B 5B 7.5B Q4 '15: 1B Q1 '16: 1.4B Q2 '16: 669.6M Q3 '16: 964M Q4 '16: 276.6M Q1 '17: 2.7B Q2 '17: 393.1M Q3 '17: 2.4B Q1 '18: 2.2B Q2 '18: 542M Q3 '18: 607M Q4 '18: 463M Q1 '19: 1.6B Q2 '19: 1.4B Q3 '19: 1.7B Q4 '19: 1.3B Q1 '20: 2.5B Q2 '20: 5.5B Q3 '20: -1.1B Q4 '20: 3.8B Q1 '21: 2.5B Q2 '21: 1.7B Q3 '21: 2.5B Q4 '21: 1.7B Q1 '22: 2.5B Q2 '22: 2.5B Q3 '22: 4.9B Q1 '23: 6.5B Q2 '23: 1.9B Q3 '23: 2.6B Q1 '24: 2B Q2 '24: 447M Q3 '24: 2.7B Q4 '24: 706M Q1 '25: 1B Q2 '25: 2.1B Q3 '25: 1.1B Q4 '25: 84M Q1 '26: 4.3B Q2 '26: 1.9B Q4 '16 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q3 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-2.5B 0 2.5B 5B 7.5B Q4 '15: 815.1M Q1 '16: 1.2B Q2 '16: 535.9M Q3 '16: 799.6M Q4 '16: 108.2M Q1 '17: 2.6B Q2 '17: 223.5M Q3 '17: 2.2B Q1 '18: 2B Q2 '18: 227M Q3 '18: 252M Q4 '18: 143M Q1 '19: 1.4B Q2 '19: 1.2B Q3 '19: 1.4B Q4 '19: 976M Q1 '20: 2.3B Q2 '20: 5.3B Q3 '20: -1.5B Q4 '20: 3.5B Q1 '21: 2.3B Q2 '21: 1.4B Q3 '21: 2.2B Q4 '21: 1.3B Q1 '22: 2.3B Q2 '22: 2.2B Q3 '22: 4.6B Q1 '23: 6.2B Q2 '23: 1.6B Q3 '23: 2.3B Q1 '24: 1.7B Q2 '24: 124M Q3 '24: 2.3B Q4 '24: 384M Q1 '25: 821M Q2 '25: 1.8B Q3 '25: 775M Q4 '25: -209M Q1 '26: 4.1B Q2 '26: 1.6B Q4 '16 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q3 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q2 '13: 303.2M Q3 '13: 304.5M Q1 '14: 292.6M Q2 '14: 286M Q3 '14: 284.1M Q1 '15: 280.4M Q2 '15: 274.3M Q3 '15: 269.2M Q1 '16: 267.5M Q2 '16: 268.2M Q3 '16: 268.1M Q1 '17: 270.4M Q2 '17: 270.8M Q3 '17: 267M Q1 '18: 262.8M Q2 '18: 264.5M Q3 '18: 265.4M Q1 '19: 262.3M Q2 '19: 261M Q3 '19: 260M Q1 '20: 256.4M Q2 '20: 255.4M Q3 '20: 254.2M Q1 '21: 248.2M Q2 '21: 247.4M Q3 '21: 246M Q1 '22: 244.4M Q2 '22: 243.4M Q3 '22: 242.2M Q1 '23: 239.7M Q2 '23: 237.8M Q3 '23: 236.5M Q1 '24: 234.2M Q2 '24: 233.4M Q3 '24: 233.1M Q1 '25: 227.2M Q2 '25: 225.8M Q3 '25: 223.7M Q1 '26: 220.4M Q2 '26: 217.9M Q3 '14 Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 10.00 20.00 30.00 Q3 '16: 8.52 Q4 '16: 9.21 Q1 '17: 10.31 Q2 '17: 10.56 Q3 '17: 11.06 Q4 '17: 14.36 Q1 '18: 15.62 Q2 '18: 16.44 Q3 '18: 17.26 Q4 '18: 14.20 Q1 '19: 15.12 Q2 '19: 15.50 Q3 '19: 16.43 Q4 '19: 18.44 Q1 '20: 18.47 Q2 '20: 23.02 Q3 '20: 19.34 Q4 '20: 17.91 Q1 '21: 18.68 Q2 '21: 17.02 Q3 '21: 22.28 Q4 '21: 24.95 Q1 '22: 25.56 Q2 '22: 25.04 Q3 '22: 25.53 Q4 '22: 24.28 Q1 '23: 25.26 Q2 '23: 26.32 Q3 '23: 25.15 Q4 '23: 25.20 Q1 '24: 26.49 Q2 '24: 28.55 Q3 '24: 27.46 Q4 '24: 25.67 Q1 '25: 25.69 Q2 '25: 23.56 Q3 '25: 24.52 Q4 '25: 25.19 Q1 '26: 23.58 Q2 '26: 22.57 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.